Cell therapy trials reported lower back-pain scores, with safety still uncertain
A pooled analysis found improvements in pain and disability scores, but its estimate for serious adverse events left substantial uncertainty.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
Somatic cell therapies were associated with better pain and disability scores in the pooled trials. Serious adverse events did not show a clear difference, but the wide confidence interval is compatible with lower or higher odds. The abstract does not establish durable benefits or identify which cell treatment should be preferred for chronic low back pain.
This abstract-based summary lacks control treatments, follow-up lengths and score ranges. The authors requested larger trials with longer follow-up, leaving the durability of benefit and choice of cell type unresolved.
What improved
The pooled analysis assessed pain with a visual analogue scale and disability with the Oswestry Disability Index. These score-based findings describe measured pain and disability; the abstract does not specify their practical importance for individual patients.
Why safety remains uncertain
The safety estimate was imprecise: its confidence interval allowed both lower and higher odds of serious adverse events. A statistically inconclusive safety result therefore cannot establish that the therapies are equally safe.
The original publication
Clinical efficacy and safety of somatic cell therapy for chronic low back pain: evidence from the pooled randomized controlled trials.
Li Z, Sun Y, Lei S et al.
Stem Cell Res Ther · 2025
- PubMed ID
- 40999526
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.